{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:00:08Z","timestamp":1790892008702,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008686","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000}}],"reference-count":93,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>The novelty of new human coronavirus COVID-19\/SARS-CoV-2 and the lack of effective drugs and vaccines gave rise to a wide variety of strategies employed to fight this worldwide pandemic. Many of these strategies rely on the repositioning of existing drugs that could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we presented a new network-based algorithm for drug repositioning, called SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), which predicts drug\u2013disease associations by quantifying the interplay between the drug targets and the disease-specific proteins in the human interactome via a novel network-based similarity measure that prioritizes associations between drugs and diseases locating in the same network neighborhoods. Specifically, we applied SAveRUNNER on a panel of 14 selected diseases with a consolidated knowledge about their disease-causing genes and that have been found to be related to COVID-19 for genetic similarity (i.e., SARS), comorbidity (e.g., cardiovascular diseases), or for their association to drugs tentatively repurposed to treat COVID-19 (e.g., malaria, HIV, rheumatoid arthritis). Focusing specifically on SARS subnetwork, we identified 282 repurposable drugs, including some the most rumored off-label drugs for COVID-19 treatments (e.g., <jats:italic>chloroquine<\/jats:italic>, <jats:italic>hydroxychloroquine<\/jats:italic>, <jats:italic>tocilizumab<\/jats:italic>, <jats:italic>heparin<\/jats:italic>), as well as a new combination therapy of 5 drugs (<jats:italic>hydroxychloroquine<\/jats:italic>, <jats:italic>chloroquine<\/jats:italic>, <jats:italic>lopinavir<\/jats:italic>, <jats:italic>ritonavir<\/jats:italic>, <jats:italic>remdesivir<\/jats:italic>), actually used in clinical practice. Furthermore, to maximize the efficiency of putative downstream validation experiments, we prioritized 24 potential anti-SARS-CoV repurposable drugs based on their network-based similarity values. These top-ranked drugs include ACE-inhibitors, monoclonal antibodies (e.g., anti-IFN\u03b3, anti-TNF\u03b1, anti-IL12, anti-IL1\u03b2, anti-IL6), and thrombin inhibitors. Finally, our findings were <jats:italic>in-silico<\/jats:italic> validated by performing a gene set enrichment analysis, which confirmed that most of the network-predicted repurposable drugs may have a potential treatment effect against human coronavirus infections.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1008686","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T05:15:43Z","timestamp":1612761343000},"page":"e1008686","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":107,"title":["SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-8203","authenticated-orcid":true,"given":"Giulia","family":"Fiscon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-1476","authenticated-orcid":true,"given":"Federica","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9393-2047","authenticated-orcid":true,"given":"Paola","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"issue":"4","key":"pcbi.1008686.ref001","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"AE Gorbalenya","year":"2020","journal-title":"Nat Microbiol"},{"key":"pcbi.1008686.ref002","doi-asserted-by":"crossref","unstructured":"Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev [Internet]. [cited 2020 Mar 19]; Available from: https:\/\/academic.oup.com\/nsr\/advance-article\/doi\/10.1093\/nsr\/nwaa036\/5775463.","DOI":"10.1093\/nsr\/nwaa036"},{"key":"pcbi.1008686.ref003","article-title":"Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses","author":"D Raoult","year":"2020","journal-title":"Cell Stress"},{"key":"pcbi.1008686.ref004","unstructured":"Coronavirus COVID-19 (2019-nCoV) [Internet]. [cited 2020 Mar 19]. Available from: https:\/\/gisanddata.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b48e9ecf6."},{"issue":"0","key":"pcbi.1008686.ref005","article-title":"Africa in the Path of Covid-19","volume":"0","author":"WM El-Sadr","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pcbi.1008686.ref006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"S Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"0","key":"pcbi.1008686.ref007","article-title":"A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"0","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"pcbi.1008686.ref008","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial","volume":"3","author":"MGS Borba","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"pcbi.1008686.ref009","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"M Wang","year":"2020","journal-title":"Cell Res"},{"issue":"0","key":"pcbi.1008686.ref010","article-title":"Remdesivir for the Treatment of Covid-19\u2014Preliminary Report","volume":"0","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"pcbi.1008686.ref011","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1002\/wsbm.1489","article-title":"Molecular networks in Network Medicine: Development and applications","volume":"12","author":"EK Silverman","year":"2020","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"1","key":"pcbi.1008686.ref012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"A-L Barab\u00e1si","year":"2011","journal-title":"Nat Rev Genet"},{"key":"pcbi.1008686.ref013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.coisb.2017.04.015","article-title":"Interactome-based approaches to human disease","volume":"3","author":"M Caldera","year":"2017","journal-title":"Curr Opin Syst Biol"},{"issue":"1","key":"pcbi.1008686.ref014","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","article-title":"Network-based approach to prediction and population-based validation of in silico drug repurposing","volume":"9","author":"F Cheng","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"pcbi.1008686.ref015","doi-asserted-by":"crossref","first-page":"e1002503","DOI":"10.1371\/journal.pcbi.1002503","article-title":"Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference","volume":"8","author":"F Cheng","year":"2012","journal-title":"PLOS Comput Biol"},{"issue":"1","key":"pcbi.1008686.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Y Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"pcbi.1008686.ref017","article-title":"Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer\u2019s Disease","author":"J Fang","year":"2020","journal-title":"medRxiv"},{"key":"pcbi.1008686.ref018","article-title":"Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19","author":"DM Gysi","year":"2020","journal-title":"ArXiv200407229 Cs Q-Bio Stat"},{"issue":"1","key":"pcbi.1008686.ref019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/bioinformatics\/btp618","article-title":"Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations","volume":"26","author":"W Yu","year":"2010","journal-title":"Bioinformatics"},{"key":"pcbi.1008686.ref020","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"DS Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"10224","key":"pcbi.1008686.ref021","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"R Lu","year":"2020","journal-title":"The Lancet"},{"issue":"10223","key":"pcbi.1008686.ref022","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N Chen","year":"2020","journal-title":"The Lancet"},{"key":"pcbi.1008686.ref023","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","author":"D Wang","year":"2020","journal-title":"JAMA"},{"key":"pcbi.1008686.ref024","author":"COVID-19: Finding the Right Fit","year":"2020","journal-title":"DrugBank Blog"},{"issue":"1","key":"pcbi.1008686.ref025","first-page":"1","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"J Liu","year":"2020","journal-title":"Cell Discov"},{"issue":"1","key":"pcbi.1008686.ref026","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"J Gao","journal-title":"Biosci Trends. 2020"},{"key":"pcbi.1008686.ref027","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","author":"P Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pcbi.1008686.ref028","article-title":"Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus","author":"MF McCarty","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"pcbi.1008686.ref029","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3201\/eid1002.030482","article-title":"Interferon-\u03b2 1a and SARS Coronavirus Replication","volume":"10","author":"LE Hensley","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pcbi.1008686.ref030","first-page":"1","article-title":"Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature","volume":"4","author":"AR Sahin","year":"2019","journal-title":"EURASIAN J Med Oncol"},{"issue":"1","key":"pcbi.1008686.ref031","first-page":"4","article-title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","volume":"7","author":"Y-H Jin","year":"2020","journal-title":"Mil Med Res"},{"issue":"3","key":"pcbi.1008686.ref032","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"CM Chu","year":"2004","journal-title":"Thorax"},{"issue":"7","key":"pcbi.1008686.ref033","article-title":"Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"9","author":"J Guo","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"pcbi.1008686.ref034","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","author":"W-J Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"pcbi.1008686.ref035","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"key":"pcbi.1008686.ref036","first-page":"1","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","author":"DE Gordon","year":"2020","journal-title":"Nature"},{"key":"pcbi.1008686.ref037","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","author":"P Mehta","year":"2020","journal-title":"The Lancet"},{"key":"pcbi.1008686.ref038","article-title":"SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems","author":"D Blanco-Melo","year":"2020","journal-title":"bioRxiv"},{"issue":"6","key":"pcbi.1008686.ref039","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles","volume":"171","author":"A Subramanian","year":"2017","journal-title":"Cell"},{"issue":"6224","key":"pcbi.1008686.ref040","doi-asserted-by":"crossref","DOI":"10.1126\/science.1257601","article-title":"Uncovering disease-disease relationships through the incomplete interactome","volume":"347","author":"J Menche","year":"2015","journal-title":"Science"},{"key":"pcbi.1008686.ref041","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-8955-3_6","volume-title":"Computational Methods for Drug Repurposing","author":"S Alaimo","year":"2019"},{"issue":"5","key":"pcbi.1008686.ref042","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/bib\/bbx017","article-title":"A review of network-based approaches to drug repositioning","volume":"19","author":"M Lotfi Shahreza","year":"2017","journal-title":"Brief Bioinform"},{"issue":"1","key":"pcbi.1008686.ref043","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"J Li","year":"2016","journal-title":"Brief Bioinform"},{"issue":"10","key":"pcbi.1008686.ref044","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of Drug Repositioning Approaches and Resources","volume":"14","author":"H Xue","year":"2018","journal-title":"Int J Biol Sci"},{"issue":"17","key":"pcbi.1008686.ref045","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1093\/bioinformatics\/btw228","article-title":"Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm","volume":"32","author":"H Luo","year":"2016","journal-title":"Bioinformatics"},{"key":"pcbi.1008686.ref046","first-page":"53","article-title":"Drug target predictions based on heterogeneous graph inference","author":"W Wang","year":"2013","journal-title":"Pac Symp Biocomput Pac Symp Biocomput"},{"issue":"1","key":"pcbi.1008686.ref047","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.artmed.2014.11.003","article-title":"DrugNet: network-based drug-disease prioritization by integrating heterogeneous data","volume":"63","author":"V Mart\u00ednez","year":"2015","journal-title":"Artif Intell Med"},{"key":"pcbi.1008686.ref048","article-title":"National Institute for the Infectious Diseases \u201cL. Spallanzani\u201d, IRCCS. Recommendations for COVID-19 clinical management","author":"E Nicastri","year":"2020","journal-title":"Infect Dis Rep"},{"key":"pcbi.1008686.ref049","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","author":"JM Sanders","year":"2020","journal-title":"JAMA"},{"key":"pcbi.1008686.ref050","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"F Touret","year":"2020","journal-title":"Antiviral Res"},{"issue":"3","key":"pcbi.1008686.ref051","doi-asserted-by":"crossref","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS-CoV-2","volume":"55","author":"P Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pcbi.1008686.ref052","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","author":"N Tang","year":"2020","journal-title":"J Thromb Haemost JTH"},{"key":"pcbi.1008686.ref053","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"C Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pcbi.1008686.ref054","article-title":"The versatile heparin in COVID-19","author":"J Thachil","year":"2020","journal-title":"J Thromb Haemost JTH"},{"issue":"0","key":"pcbi.1008686.ref055","article-title":"Compassionate Use of Remdesivir for Patients with Severe Covid-19","volume":"0","author":"J Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"pcbi.1008686.ref056","unstructured":"FDA Approves First Treatment for COVID-19 [Internet]. FDA. FDA; 2020 [cited 2020 Nov 2]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"pcbi.1008686.ref057","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.cct.2020.106165","article-title":"TOCIVID-19\u2014A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia","volume":"98","author":"MC Piccirillo","year":"2020","journal-title":"Study protocol. Contemp Clin Trials"},{"key":"pcbi.1008686.ref058","unstructured":"Hoffmann-La Roche. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia [Internet]. clinicaltrials.gov; 2020 Sep [cited 2020 Oct 29]. Report No.: NCT04320615. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320615."},{"key":"pcbi.1008686.ref059","unstructured":"Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2020 Nov 2]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=214787."},{"key":"pcbi.1008686.ref060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/PGPM.S275964","article-title":"Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine","volume":"13","author":"M Babayeva","year":"2020","journal-title":"Pharmacogenomics Pers Med"},{"key":"pcbi.1008686.ref061","unstructured":"Commissioner O of the. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine [Internet]. FDA. FDA; 2020 [cited 2020 Nov 2]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and."},{"key":"pcbi.1008686.ref062","article-title":"Repurposed antiviral drugs for COVID-19 \u2013interim WHO SOLIDARITY trial results","author":"Consortium WS trial","year":"2020","journal-title":"medRxiv"},{"issue":"2","key":"pcbi.1008686.ref063","doi-asserted-by":"crossref","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a therapy for COVID-19: current evidence and future possibilities","volume":"319","author":"JA Hippensteel","year":"2020","journal-title":"Am J Physiol-Lung Cell Mol Physiol"},{"key":"pcbi.1008686.ref064","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01307","article-title":"The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review","volume":"11","author":"L Gozzo","year":"2020","journal-title":"Front Pharmacol"},{"issue":"20","key":"pcbi.1008686.ref065","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"S Richardson","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"pcbi.1008686.ref066","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"L Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pcbi.1008686.ref067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09692-y","article-title":"Network-based prediction of drug combinations","volume":"10","author":"F Cheng","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"pcbi.1008686.ref068","article-title":"Outcomes in Patients with COVID-19 Infection Taking ACEI\/ARB","volume":"22","author":"JS Rico-Mesa","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"pcbi.1008686.ref069","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"L Fang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"0","key":"pcbi.1008686.ref070","first-page":"E014","article-title":"Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia","volume":"43","author":"ML Sun","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin J Tuberc Respir Dis"},{"key":"pcbi.1008686.ref071","article-title":"COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up","author":"B Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1\u20132","key":"pcbi.1008686.ref072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.02.007","article-title":"Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway","volume":"128","author":"W Wang","year":"2007","journal-title":"Virus Res"},{"issue":"5","key":"pcbi.1008686.ref073","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","article-title":"Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?","volume":"69","author":"M Garg","year":"2020","journal-title":"Gut"},{"issue":"11","key":"pcbi.1008686.ref074","article-title":"Adalimumab for induction of remission in Crohn\u2019s disease","volume":"2019","author":"M Abbass","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10234","key":"pcbi.1008686.ref075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"M Feldmann","year":"2020","journal-title":"The Lancet"},{"key":"pcbi.1008686.ref076","unstructured":"Chinese Clinical Trial Register (ChiCTR)\u2014The world health organization international clinical trials registered organization registered platform [Internet]. [cited 2020 May 13]. Available from: http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49889."},{"issue":"4","key":"pcbi.1008686.ref077","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"J Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10223","key":"pcbi.1008686.ref078","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"pcbi.1008686.ref079","doi-asserted-by":"crossref","first-page":"104803","DOI":"10.1016\/j.phrs.2020.104803","article-title":"Statins in coronavirus outbreak: It\u2019s time for experimental and clinical studies","volume":"156","author":"M Bifulco","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5","key":"pcbi.1008686.ref080","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e33","article-title":"Direct Antiviral Mechanisms of Interferon-Gamma","volume":"18","author":"S Kang","year":"2018","journal-title":"Immune Netw"},{"issue":"23","key":"pcbi.1008686.ref081","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in Inflammatory Disease","volume":"20","author":"S Kany","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"pcbi.1008686.ref082","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"P Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"pcbi.1008686.ref083","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"214","author":"W Zhang","year":"2020","journal-title":"Clin Immunol Orlando Fla"},{"issue":"1","key":"pcbi.1008686.ref084","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"MJ Cameron","year":"2008","journal-title":"Virus Res"},{"issue":"2","key":"pcbi.1008686.ref085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"X Li","year":"2020","journal-title":"J Pharm Anal"},{"issue":"1","key":"pcbi.1008686.ref086","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the Eye of the Cytokine Storm","volume":"76","author":"JR Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev MMBR"},{"issue":"2","key":"pcbi.1008686.ref087","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ng0208-124","article-title":"A navigator for human genome epidemiology","volume":"40","author":"W Yu","year":"2008","journal-title":"Nat Genet"},{"issue":"D1","key":"pcbi.1008686.ref088","first-page":"D1031","article-title":"Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics","volume":"48","author":"Y Wang","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"pcbi.1008686.ref089","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"M Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"pcbi.1008686.ref090","doi-asserted-by":"crossref","first-page":"066111","DOI":"10.1103\/PhysRevE.70.066111","article-title":"Finding community structure in very large networks","volume":"70","author":"A Clauset","year":"2004","journal-title":"Phys Rev E"},{"key":"pcbi.1008686.ref091","first-page":"e502809","volume-title":"Mathematical Problems in Engineering","author":"V da F Vieira","year":"2014"},{"issue":"6","key":"pcbi.1008686.ref092","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/wics.1319","article-title":"Community detection in large-scale networks: a survey and empirical evaluation","volume":"6","author":"S Harenberg","year":"2014","journal-title":"WIREs Comput Stat"},{"issue":"5","key":"pcbi.1008686.ref093","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters","volume":"16","author":"G Yu","year":"2012","journal-title":"OMICS J Integr Biol"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008686","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T21:05:36Z","timestamp":1613682336000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008686"}},"subtitle":[],"editor":[{"given":"Manja","family":"Marz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008686","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1008686","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]}}}